Free Trial

Allergy Therapeutics (LON:AGY) Stock Crosses Above 50 Day Moving Average - Time to Sell?

Allergy Therapeutics logo with Medical background

Allergy Therapeutics plc (LON:AGY - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 7.20 ($0.10) and traded as high as GBX 8.10 ($0.11). Allergy Therapeutics shares last traded at GBX 8.10 ($0.11), with a volume of 260,751 shares trading hands.

Allergy Therapeutics Stock Performance

The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63. The firm has a market cap of £393.21 million, a PE ratio of -7.71, a PEG ratio of -30.70 and a beta of 1.40. The stock's 50 day simple moving average is GBX 7.23 and its 200 day simple moving average is GBX 6.78.

Allergy Therapeutics Company Profile

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Featured Stories

Should You Invest $1,000 in Allergy Therapeutics Right Now?

Before you consider Allergy Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.

While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines